Fig. 3

P-tau217 Outperforms p-tau181 for the Detection of Aβ Positivity in Individuals with MCI/Dementia. Plasma samples were analysed for both p-tau181 and p-tau217. A P-tau181 was 1.7 times higher in Aβ + vs Aβ- individuals (Mann–Whitney U = 661; p < 0.001). B p-tau181 exhibited inferior performance than p-tau217 in the detection of Aβ + status (Area-Under the Curve [AUC]: 0.91; 0.86–0.97 for p-tau217 vs 0.72; 0.62–0.83, DeLong test p < 0.001). C Significant differences were not seen in concentrations of p-tau181 between A- T- and A- T + individuals or between A + T- and A + T + individuals. D There were no significant differences between dementia and MCI for either Aβ + or Aβ – groups. E Significant correlations were seen between plasma p-tau181 and plasma p-tau217 in Aβ + (Spearman’s R = 0.60, p < 0.001) but not Aβ – (Spearman’s R = 0.16, p = 0.34) individuals. F Significant correlations were seen between CSF p-tau181 and plasma p-tau217 again in Aβ + (Spearman’s R = 0.63, p < 0.001) but not Aβ – (Spearman’s R = 0.10, p = 0.60) individuals. ****p < 0.0001, ***p < 0.001, ** < 0.01, *p < 0.05, ns: non-significant; AUC: Area-Under-the-Curve